2月25日 - ** 万达制药VNDA.O股价盘前上涨5.39%，报8.61美元
** 制药商称美国FDA接受了其对imsidolimab的审查申请，该药用于治疗泛发性脓疱型银屑病，一种会导致皮肤出现疼痛脓疱、发烧和疲劳的罕见疾病。
** 公司补充说，在试验中，50% 以上的患者服用单剂量药物后症状消失，而安慰剂组只有 13% 的患者症状消失
** 称长期用药的患者在长达两年的时间里没有再复发--皮肤疼痛症状突然复发
** 预计美国FDA将于 12 月 12 日做出决定 - VNDA
** 2025年VNDA股价上涨84%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.